164 related articles for article (PubMed ID: 2841895)
1. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.
Hainsworth JD; Johnson DH; Greco FA
Ann Intern Med; 1988 Sep; 109(5):364-71. PubMed ID: 2841895
[TBL] [Abstract][Full Text] [Related]
2. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
Hainsworth JD; Greco FA
Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
[TBL] [Abstract][Full Text] [Related]
3. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Dial TW; Greco FA
Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
Hainsworth JD; Johnson DH; Greco FA
J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
[TBL] [Abstract][Full Text] [Related]
5. The role of cisplatin/bleomycin-based chemotherapy in the treatment of poorly differentiated carcinoma of unknown primary site.
Hainsworth JD; Johnson DH; Greco FA
Semin Oncol; 1992 Apr; 19(2 Suppl 5):54-7; discussion 58. PubMed ID: 1384145
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine carcinoma of unknown primary site.
Spigel DR; Hainsworth JD; Greco FA
Semin Oncol; 2009 Feb; 36(1):52-9. PubMed ID: 19179188
[TBL] [Abstract][Full Text] [Related]
7. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining.
Hainsworth JD; Wright EP; Johnson DH; Davis BW; Greco FA
J Clin Oncol; 1991 Nov; 9(11):1931-8. PubMed ID: 1941051
[TBL] [Abstract][Full Text] [Related]
8. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
[TBL] [Abstract][Full Text] [Related]
9. Poorly differentiated carcinoma and germ cell tumors.
Hainsworth JD; Greco FA
Hematol Oncol Clin North Am; 1991 Dec; 5(6):1223-31. PubMed ID: 1663941
[TBL] [Abstract][Full Text] [Related]
10. Etoposide/cisplatin-based chemotherapy for patients with metastatic poorly differentiated carcinoma of unknown primary site.
Greco FA; Johnson DH; Hainsworth JD
Semin Oncol; 1992 Dec; 19(6 Suppl 13):14-8. PubMed ID: 1492223
[TBL] [Abstract][Full Text] [Related]
11. Advanced poorly differentiated carcinoma of unknown primary site: recognition of a treatable syndrome.
Greco FA; Vaughn WK; Hainsworth JD
Ann Intern Med; 1986 Apr; 104(4):547-53. PubMed ID: 3006571
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.
Hainsworth JD; Lennington WJ; Greco FA
J Clin Oncol; 2000 Feb; 18(3):632-5. PubMed ID: 10653878
[TBL] [Abstract][Full Text] [Related]
13. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
Greco FA; Hainsworth JD
Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic management of cancer of unknown primary site by pathological types].
Fernández Cotarelo MJ; Guerra Vales JM
Rev Clin Esp; 2009 Oct; 209(9):439-43. PubMed ID: 19852914
[TBL] [Abstract][Full Text] [Related]
15. Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR.
Tauchmanovà L; Pensabene M; Capuano I; Spagnoletti I; Zeppa P; Del Vecchio S; Mainenti M; De Rosa G; Colao A; Contegiacomo A
J Endocrinol Invest; 2005 Apr; 28(4):371-8. PubMed ID: 15966513
[TBL] [Abstract][Full Text] [Related]
16. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity?
Shia J; Tang LH; Weiser MR; Brenner B; Adsay NV; Stelow EB; Saltz LB; Qin J; Landmann R; Leonard GD; Dhall D; Temple L; Guillem JG; Paty PB; Kelsen D; Wong WD; Klimstra DS
Am J Surg Pathol; 2008 May; 32(5):719-31. PubMed ID: 18360283
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors.
Stoyianni A; Pentheroudakis G; Pavlidis N
Cancer Treat Rev; 2011 Aug; 37(5):358-65. PubMed ID: 21481536
[TBL] [Abstract][Full Text] [Related]
18. The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary.
van der Gaast A; Verwij J; Planting AS; Stoter G; Henzen-Logmans SC
J Cancer Res Clin Oncol; 1996; 122(3):181-85. PubMed ID: 8601568
[TBL] [Abstract][Full Text] [Related]
19. [Metastatic carcinoma of unknown origin].
Fizazi K; Culine S
Bull Cancer; 1998 Jul; 85(7):609-17. PubMed ID: 9752267
[TBL] [Abstract][Full Text] [Related]
20. Multiple bilateral choroidal metastatic tumors from a small-cell neuroendocrine carcinoma of unknown primary site.
Nicolò M; Piccolino FC; Ghiglione D; Nicolò G; Calabria G
Eur J Ophthalmol; 2005; 15(1):148-52. PubMed ID: 15751257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
